DHR Maintained by TD Cowen -- Price Target Raised to $270

TD Cowen raised Danaher Corporation's (DHR) price target to $270 from $255, maintaining a 'Buy' rating. DHR is currently trading at $234.23, slightly below its GF Value™ of $236.37. The company has a GF Score™ of 81/100, indicating strong performance, and is held by 26 gurus, with 18 increasing their positions.

Original reporting
Published Oct 22, 2026, 2:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 2:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$DHR
Bullish
medium confidence
Mentioned
$DHR
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$DHRBullishMed
01

Why it matters

The price‑target raise signals confidence in Danaher's growth trajectory, potentially prompting short‑term buying while the modest upside may limit large inflows.

02

Market read

Analyst target lifts are a common catalyst for short‑term price moves in large‑cap stocks like DHR.

03

What to watch

Recent insider selling could temper enthusiasm despite the higher target.

Relevance 7/10Novelty 7/10Timing: today

Background

Danaher is a diversified life‑sciences and diagnostics company with a market cap of ~$165B. The analyst update follows a period of strong guru buying and recent insider sales.

Company-level read

Ticker impact

$DHRBullishMedium confidence
Context

TD Cowen raised its price target for Danaher Corp. (DHR) from $255 to $270 and kept a Buy rating, indicating fresh analyst optimism.

Expected impact

likely upward pressure as market prices in the higher target

Evidence & confidence

The target raise is a new analyst action with a specific price level, suggesting short‑term buying interest.

Market effects

May boost sentiment for the broader healthcare/diagnostics sector as Danaher is a bellwether.

U.S. market focus; limited regional effect.

Modest, primarily influences investors tracking large‑cap US healthcare stocks.

Counterpoint

Some investors may view the modest target increase as insufficient given the high current valuation.

Key entities

  • TD Cowen

    Equity research firm that issued the rating update.

  • Danaher Corporation

    Subject of the rating update.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.

$DHRMed

Stifel maintains Buy rating on Danaher, $260 price target

Stifel maintained a Buy rating on Danaher with a $260 price target, suggesting 11.2% upside from the Oct 21 close. The firm cited strong financial performance, including 8.5% revenue growth and a 29.0% adjusted operating profit margin, as well as positive growth prospects under new leadership.